This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07163624 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 211 participants |
| Design | Interventional, Randomized, Parallel, Double-blind, Placebo- and active-controlled |
| Conditions | Type 2 Diabetes Mellitus |
| Interventions | UBT251 Injection 2.0 mg; UBT251 Injection 4.0 mg (initial dose 0.5 mg); UBT251 Injection 4.0 mg (initial dose 1.0 mg); UBT251 Injection 6.0 mg; Semaglutide Injection (Ozempic); Placebo |
| Start | Mar 22, 2025 |
| Primary completion | Nov 21, 2025 |
| Study completion | Dec 30, 2025 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Evaluates the efficacy of UBT251 injection after 24 weeks of continuous administration in type 2 diabetes and aims to recommend the dosing regimen for the phase 3 program. Results are published in Cell Metabolism.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from baseline in HbA1c at Week 24 | Baseline to week 24 |
12 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Dose-Finding Study in Type 2 Diabetes (Novo Nordisk Phase 2) (Phase 2 NCT07668388)
- UNIGUIDE-1: UBT251 Phase 3 in Type 2 Diabetes on Diet and Exercise Alone (Phase 3 NCT07659574)
- UNIGUIDE-2: UBT251 Phase 3 Against Semaglutide in Type 2 Diabetes (Phase 3 NCT07653477)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP) (Phase 3 NCT07767942)
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
